ReviewHypertension (Dallas, Tex. : 1979)2020
Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium.
Review in Hypertension (Dallas, Tex. : 1979), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Guidelines for the appropriate use of renal denervation systems in Japan: endorsed by the Japanese Society of Hypertension (JSH), the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS), and their positioning in the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- Impact of renal denervation on cardiac remodeling in resistant hypertension: A meta-analysis.Clinical cardiology · 2024Pooled it
- Effect of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach.Journal of hypertension · 2022Trial
- Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Trial
- Renal denervation triage tool: a practical approach to the management of resistant hypertension.AsiaIntervention · 2026Review
- Renal Denervation in Asia: 2025 Asia Renal Denervation Consortium (ARDeC) Consensus Statement Endorsed by the Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Cost-Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Renal Denervation After USA FDA Approval: An Update from an Interventional Cardiologist's Perspective.Journal of clinical medicine · 2025Review
- An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.Current treatment options in cardiovascular medicine · 2025Article
- Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Cost-Effectiveness of Radiofrequency Renal Denervation for Uncontrolled Hypertension in Japan.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- What are the ideal metrics for assessing the quality of long-term stabilized "perfect" 24-h BP control after renal denervation?Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Consensus statement on renal denervation by the Joint Committee of Japanese Society of Hypertension (JSH), Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS).Cardiovascular intervention and therapeutics · 2024Article
- Research status and frontiers of renal denervation for hypertension: a bibliometric analysis from 2004 to 2023.Journal of health, population, and nutrition · 2024Article
- Catheter-Based Renal Denervation Ready for the Management of Hypertension: Evidence, Challenges, and Perspectives.Journal of the American Heart Association · 2024Article
- Patient Preference for Catheter-Based Hypertension Therapy and Subgroup Analysis: A Pilot Study Based on Taiwan Consensus on Renal Denervation.Acta Cardiologica Sinica · 2024Article
- 2023 update and perspectives.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- What impacts do the new ESH 2023 guidelines have on the management of hypertension in Japan?Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Effectiveness of Valsartan's Single-Pill Combination Therapies on Blood Pressure Control in Hypertensive Patients: Malaysian Single-Centre Real-World Experience.The Malaysian journal of medical sciences : MJMS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Asia Renal Denervation Consortium consensus conference of Asian physicians actively performing renal denervation (RDN) was recently convened to share up-to-date information and regional perspectives, with the goal of consensus on RDN in Asia. First- and second-generation trials of RDN have demonstrated the efficacy and safety of this treatment modality for lowering blood pressure in patients with resistant hypertension. Considering the ethnic differences of the hypertension profile and demographics of cardiovascular disease demonstrated in the SYMPLICITY HTN (Renal Denervation in Patients With Uncontrolled Hypertension)-Japan study and Global SYMPLICITY registry data from Korea and Taiwan, RDN might be an effective hypertension management strategy in Asia. Patient preference for device-based therapy should be considered as part of a shared patient-physician decision process. A practical population for RDN treatment could consist of Asian patients with uncontrolled essential hypertension, including resistant hypertension. Opportunities to refine the procedure, expand the therapy to other sympathetically mediated diseases, and explore the specific effects on nocturnal and morning hypertension offer a promising future for RDN. Based on available evidence, RDN should not be considered a therapy of last resort but as an initial therapy option that may be applied alone or as a complementary therapy to antihypertensive medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.